Healthcare
Glaukos Corporation(GKOS)
Live Price
Offline$126.81
+2.05% today
1Y Change
+33.24%
Window
Jun 26, 2025 โ Jun 23, 2026
- Market Cap
- $8.14B
- Revenue Growth
- +32.3%
- EPS Growth
- -18.4%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 26, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Glaukos Corporation (GKOS) is a Healthcare stock with a market cap of $8.14B and listed on NYSE. The stock last traded around $126.81 and up 33.2% across the available one-year price window (Jun 26, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +32.3%, EPS growth of -18.4%, a dividend yield of 0.0%. What stands out right now is revenue +32.3%, EPS -18.4%, free cash flow +20.1% with operating margin -14.0% and ROIC -9.4%. Valuation already assumes a fairly strong business story at price/sales 14.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GKOS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+32.3% vs +7.6% peer median
Operating Margin
Below sector median
-14.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +32.3% and EPS is at -18.4%, with operating margin around -14.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +12.3% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +22.8% | +15.7% | -8.9% |
2026 Feb 17, 2026 | -27.3% | +13.5% | +11.7% | -3.5% |
2025 Oct 29, 2025 | +40.7% | +13.9% | +9.4% | +36.7% |
Benchmark Edge
GKOS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GKOS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GKOS Max Drawdown
-29.92%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GKOS and SPY.
Company Overview
Glaukos Corporation
New York Stock Exchange
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
- Leadership
- Thomas William Burns
- IPO Date
- Jun 25, 2015
- Employees
- 995
- Street Address
- 229 Avenida Fabricante
- Mailing
- Aliso Viejo, CA, 92672
- Region
- Aliso Viejo, CA, US
- Reporting Currency
- USD
- Investor Line
- 949 367 9600
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 14.8
- Price/Book
- 12.0
Growth
- Revenue
- +32.3%
- EPS
- -18.4%
- Free Cash Flow
- +20.1%
Profitability
- Gross Margin
- 79.6%
- Operating Margin
- -14.0%
- Net Margin
- -34.3%
- ROE
- -26.5%
- ROIC
- -9.4%
Balance Sheet
- Debt/Equity
- 0.15
- Current Ratio
- 5.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.